http://www.futurescience.com/hgh.html

Tesamorelin has produced many encouraging results, including a small improvement in glucose levels in most patients.   Human growth hormone often produces a temporary increase in insulin resistance when it is first started, especially in high doses.   Tesamorelin seems to have the opposite effect.

Another long-acting analog of GHRH that looks very promising is CJC-1295, but that product is at least 3 years away from approval by government agencies.  CJC-1295 maintains a much longer half-life in the human body by partially binding to albumin, an important protein that is prevalent in the human bloodstream.

As stated earlier, pharmaceutical companies have produced growth hormone releasing agents that have been shown to be very effective in reversing the decline in HGH production with age.   The one that has consistently worked the best is MK-0677 (ibutamoren mesylate), which is very effective in restoring HGH release in middle-aged and "normally-aging" elderly individuals to the levels of much younger people.   

MK-0677 is an oral medicine that restores the release of HGH in the pulsatile fashion characteristic of HGH release in young people.   

   Restoring HGH in "normally-aging" people is not a function that the Food and Drug Administration (FDA) considers to be a legitimate function of a medicine; therefore, Merck (the pharmaceutical company) stopped all further development of MK-0677.   Other effective oral HGH releasers developed by the pharmaceutical companies have faced a similar fate for similar reasons.

A considerable amount of research has been done on HGH releasers by the pharmaceutical companies, and some very promising substances have been developed, but there is no sign that any of them will be on the market anytime soon.   MK-0677 (ibutamoren mesylate) is a substance, though, that seems to be too good to go away.   It still appears in successful clinical trials from time to time.   It recently completed another successful medical test in normally aging adults, and has been undergoing clinical trials for use in fibromyalgia.

In a free market, MK-0677 (ibutamoren mesylate) would likely have had a revolutionary impact on the health of most people over 40.   In fact, it is possible that MK-0677 could have revolutionized health care, prevented great human suffering, and literally saved trillions of dollars in health care.    Since a free market in pharmaceuticals does not exist, MK-0677 will probably remain a hidden gray market gem for many years.